JP2015501820A5 - - Google Patents

Download PDF

Info

Publication number
JP2015501820A5
JP2015501820A5 JP2014546301A JP2014546301A JP2015501820A5 JP 2015501820 A5 JP2015501820 A5 JP 2015501820A5 JP 2014546301 A JP2014546301 A JP 2014546301A JP 2014546301 A JP2014546301 A JP 2014546301A JP 2015501820 A5 JP2015501820 A5 JP 2015501820A5
Authority
JP
Japan
Prior art keywords
compound
group
deuterated
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014546301A
Other languages
English (en)
Japanese (ja)
Other versions
JP5933746B2 (ja
JP2015501820A (ja
Filing date
Publication date
Priority claimed from CN2011104188590A external-priority patent/CN103159680A/zh
Application filed filed Critical
Publication of JP2015501820A publication Critical patent/JP2015501820A/ja
Publication of JP2015501820A5 publication Critical patent/JP2015501820A5/ja
Application granted granted Critical
Publication of JP5933746B2 publication Critical patent/JP5933746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014546301A 2011-12-14 2012-12-13 イミダゾリジンジオン系化合物およびその用途 Active JP5933746B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011104188590A CN103159680A (zh) 2011-12-14 2011-12-14 咪唑二酮类化合物及其用途
CN201110418859.0 2011-12-14
PCT/CN2012/086573 WO2013087004A1 (zh) 2011-12-14 2012-12-13 咪唑二酮类化合物及其用途

Publications (3)

Publication Number Publication Date
JP2015501820A JP2015501820A (ja) 2015-01-19
JP2015501820A5 true JP2015501820A5 (enExample) 2015-04-23
JP5933746B2 JP5933746B2 (ja) 2016-06-15

Family

ID=48583248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546301A Active JP5933746B2 (ja) 2011-12-14 2012-12-13 イミダゾリジンジオン系化合物およびその用途

Country Status (9)

Country Link
US (1) US9346764B2 (enExample)
EP (1) EP2792674B1 (enExample)
JP (1) JP5933746B2 (enExample)
CN (2) CN103159680A (enExample)
AU (1) AU2012350482B2 (enExample)
CA (1) CA2859224C (enExample)
ES (1) ES2587903T3 (enExample)
PL (1) PL2792674T3 (enExample)
WO (1) WO2013087004A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2908326C (en) * 2013-05-29 2017-09-12 Hinova Pharmaceuticals Inc. Imidazolidinedione compounds and their uses
CA2921156A1 (en) * 2013-09-19 2015-03-26 Glaxosmithkline Llc Combination drug therapy
CN106543085A (zh) * 2013-10-14 2017-03-29 杭州普晒医药科技有限公司 恩杂鲁胺的固态形式及其制备方法和用途
CN104803919A (zh) * 2014-01-26 2015-07-29 上海医药工业研究院 用于制备恩杂鲁胺中间体的方法
US10131636B2 (en) * 2014-10-01 2018-11-20 Laurus Labs Limited Process for the preparation of Enzalutamide
CN106432090B (zh) * 2015-10-30 2019-08-20 成都海创药业有限公司 一种氘代咪唑酮化合物的晶型及其制备方法和用途
CN107303278B (zh) * 2016-04-25 2020-11-13 成都海创药业有限公司 一种hc-1119固体分散体及其制备方法
CN107954936B (zh) * 2016-10-17 2021-03-19 海创药业股份有限公司 一种制备氘代咪唑二酮类化合物的方法
CA3053805C (en) 2017-02-13 2020-06-30 Kangpu Biopharmaceuticals, Ltd. Combination treating prostate cancer, pharmaceutical composition and treatment method
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
CA3095221A1 (en) * 2018-03-29 2019-10-03 Hinova Pharmaceuticals Inc. Deuterated imidazolidinedione compounds and their uses
CN110372598A (zh) * 2018-04-13 2019-10-25 成都海创药业有限公司 一种合成氘代酰胺及氘代磺酰胺的新方法
US20210290553A1 (en) * 2018-05-14 2021-09-23 Hinova Pharmaceuticals Inc. Hc-1119 formulation, preparation method and use thereof
WO2020095183A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combination for treating cancer
CN112442009B (zh) * 2019-08-30 2023-10-03 润佳(苏州)医药科技有限公司 氘代化合物及其在治疗癌症方面的应用
EP4122925A4 (en) * 2020-03-17 2024-04-17 Medshine Discovery Inc. Proteolysis regulator and method for using same
JP2023537595A (ja) 2020-08-13 2023-09-04 ファイザー・インク 併用治療
CN114181155A (zh) * 2021-12-21 2022-03-15 上海朝晖药业有限公司 碘-恩杂鲁胺及其制备方法及其应用
CN115181043B (zh) * 2022-07-27 2024-05-07 爱斯特(成都)生物制药股份有限公司 一种连续流制备4-异硫氰基-2-(三氟甲基)苯甲腈的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3106162A1 (en) 2005-05-13 2016-12-21 The Regents of the University of California Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
EP2656842B1 (en) * 2006-03-27 2016-08-10 The Regents of The University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2007127010A2 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
CN101817787B (zh) * 2009-02-26 2013-07-24 童友之 抗前列腺癌的雄性激素受体拮抗剂
JP5659232B2 (ja) 2009-09-10 2015-01-28 トン、ヨウヂ アンドロゲン受容体アンタゴニストおよびその使用
WO2013067151A1 (en) * 2011-11-02 2013-05-10 Medivation Prostate Therapeutics, Inc. Treatment methods using diarylthiohydantoin derivatives

Similar Documents

Publication Publication Date Title
JP2015501820A5 (enExample)
JP2013543842A5 (enExample)
JP2013542261A5 (enExample)
JP2013032389A5 (enExample)
JP2010500343A5 (enExample)
JP2014511892A5 (enExample)
JP2014500861A5 (enExample)
JP2009263394A5 (enExample)
JP2017524025A5 (enExample)
JP2011500758A5 (enExample)
RU2015108898A (ru) 3-ЦИКЛОГЕКСЕНИЛ И ЦИКЛОГЕКСИЛ ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ И ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ
JP2015512943A5 (enExample)
JP2007515465A5 (enExample)
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
JP2014500870A5 (enExample)
JP2011518833A5 (enExample)
JP2014508752A5 (enExample)
JP2010529994A5 (enExample)
JP2018537535A5 (enExample)
JP2012512863A5 (enExample)
JP2011088926A5 (enExample)
JP2015500842A5 (enExample)
JP2012509265A5 (enExample)
RU2014132159A (ru) Соединения 2-арилбензофуран-7-формамида, способ их получения и применение
JP2013525490A5 (enExample)